Dr. Brosius graduated from the University of Kansas and performed internal medicine training at the University of Michigan followed by fellowship training at the Beth Israel Hospital and Harvard Medical School in Boston. He was appointed chief of the nephrology division in 2004. He specializes in the study and treatment of patients with diabetic kidney disease.
Dr. Brosius' research focuses on molecular and translational kidney research with the goal of developing effective new treatments for diabetic complications. He has studied diabetic kidney disease mechanisms for over 20 years and for 10 years was one of the principal investigators in the NIH Animal Models of Diabetic Complications Consortium. More recently, as part of a large team-science approach he has worked to uncover the transcriptomic, proteomic and metabolite profiles of microvascular diabetic complications in both humans and mouse models. This research led directly to the discovery of JAK/STAT signaling in human diabetic kidney disease and is the basis of 2 large multi-investigator grants as well as a recently completed and highly positive phase 2 randomized clinical trial in patients with diabetic kidney disease. Recently, a long-term interest in the role of glucose transporters in vascular pathophysiology has dovetailed with this focus on diabetic complications and led to new pilot funding for examining COX inhibition in vascular abnormalities in hypertension and chronic kidney disease
- Berthier CC, Zhang H, Schin ML, Henger A, Nelson RG, Yee B, Boucherot A, Carter-Su C, Argetsinger LS, Rastaldi MP, Brosius FC*, Kretzler, M. Enhanced Expression of JAK-STAT Pathway Members in Human Diabetic Nephropathy, Diabetes, 2009, Feb;58(2):469-77. PMC2628622 (*FCB-corresponding author).
- Brosius FC 3rd, Alpers CW. New Targets for Treatment of Diabetic Nephropathy: What We Have Learned from Animal Models, Current Opinion in Nephrology and Hypertension, 2013;22(1):17-25. PMC3776427
- Hodgin JB. Nair V, Zhang H, Randolph A, Harris RC, Nelson RG, Weil EJ, Patel J, Brosius FC 3rd*, Kretzler M. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes. 2013;62(1):299-308. PMC3526018 (*FCB - corresponding author).
- Hur J, Dauch JR, Hinder LM, Hayes JM, Backus C, Pennathur S, Kretzler M, Brosius FC 3rd, Feldman EL. The Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes. Diabetes. 2015; 64:3294-3304
- Dugan LL, You YH, Ali SS, Diamond-Stanic M, Miyamoto S, DeCleves AE, Andreyev A, Quach T, Ly S, Shekhtman G, Nguyen W, Chepetan A, Le TP, Wang L, Xu M, Paik KP, Fogo A, Viollet B, Murphy A, Brosius F, Naviaux RK, Sharma K. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest,123(11):4888-99, 2013. PMC3809777